SciBase Holding AB (STO: SCIB), a Swedish developer of augmented intelligence-based solutions for skin disorders, announced on Thursday that it has on-boarded several US dermatology practices that specialise in skin cancer detection, diagnosis and treatment.

Through these practices, the company intends to further its mission to improve results for patients and clinicians by expanding access of the Nevisense test to additional states in the USA.

Dr Michael McPhee, surgical oncologist, owner and managing director of the Melanoma Clinic in Orlando, Florida, said: "The innovative Nevisense test provides us the point-of-care capability in diagnosing melanoma at the earliest possible stage. This is extremely important for our patients because early-stage melanoma is almost 100% curable. Given that melanoma is the deadliest form of skin cancer with about 20 people dying of the disease per day in the US, early detection becomes critical to survival."